At the time, Dr. Scott Gottlieb, a former FDA commissioner, said the treatment might help patientsHe did agree that convalescent plasma "certainly" met the standard for an emergency use approval "in the setting of a public health emergency."
The plasma, which is taken from patients who have recovered from Covid-19 and developed antibodies against the virus, is infused in sick patients. Scientists had hoped it would help kick-start the immune system in those patients to fight the virus., REMAP-CAP, an international clinical trial exploring potential treatments for Covid, halted its study testing convalescent blood plasma after trial investigators found no benefit.
The NIH trial was conducted at 47 hospital emergency departments across the United States and had enrolled 511 of the 900 participant recruitment goal. After the study participants received either the plasma or a placebo, researchers tracked whether the participants needed to seek further emergency or urgent care, had to be hospitalized, or died within 15 days of entering the trial.
We make sure that the people are safe. AtlAuthor
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.